Supplementary Materials

Supplementary Material for:

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

Natalia Arenas-Ramirez, Chao Zou, Simone Popp, Daniel Zingg, Barbara Brannetti, Emmanuelle Wirth, Thomas Calzascia, Jiri Kovarik, Lukas Sommer, Gerhard Zenke, Janine Woytschak, Catherine H. Regnier, Andreas Katopodis, Onur Boyman*

*Corresponding author. Email: onur.boyman{at}uzh.ch

Published 30 November 2016, Sci. Transl. Med. 8, 367ra166 (2016)
DOI: 10.1126/scitranslmed.aag3187

This PDF file includes:

  • Fig. S1. Rational screening method for generation of selective anti–hIL-2 antibodies.
  • Fig. S2. SPR probing association of CD25 or CD122 with hIL-2 bound to NARA1 or mAbcap.
  • Fig. S3. SPR assessing binding of hIL-2 or mIL-2 to NARA1 or mAbdet.
  • Fig. S4. Assessment of IL-2 binding sites of S4B6 versus NARA1 and conformational changes to the helix C of hIL-2 upon NARA1 binding.
  • Fig. S5. Linear peptide epitope mapping of NARA1 and mAbdet binding sites on unmodified hIL-2 and hIL-2 muteins.
  • Fig. S6. In vivo half-life of hIL-2 and hIL-2/NARA1 complexes.
  • Fig. S7. In vivo effects of Fc-competent and Fc-silent hIL-2/NARA1 complexes.
  • Fig. S8. In vivo effects of titrated amounts of hIL-2 and hIL-2/NARA1 complexes.
  • Fig. S9. In vitro effects of hIL-2 and hIL-2/NARA1 complexes made of fulllength, Fab, and F(ab′)2 fragments of NARA1.
  • Fig. S10. Effects of hIL-2/NARA1 complexes on anti–B16-F10 melanoma response in wild-type mice versus different immune cell–deficient animals.
  • Fig. S11. Short-term adverse effects of titrated doses of hIL-2 and hIL-2/NARA1 complexes in vivo.
  • Fig. S12. Long-term adverse effects of hIL-2 or hIL-2/NARA1 complex immunotherapy.
  • Table S1. Antibodies used for flow cytometry.

[Download PDF]